Vaccine developer Moderna shared trial data this week showing its new COVID-19 bivalent booster is effective at protecting against the BA.4 and BA.5 omicron subvariants.
But the good news may have come too little, too late.
BA.5 — once the dominant variant during the summer months — now makes up less than a third of new COVID-19 cases heading into the holidays. Edging it out are sublineages BQ.1 and BQ.1.1, which make up nearly half of new cases and appear to be gaining ground.
Although not much is known about the newest strains, experts say the bivalent booster should offer some protection. Here’s what you should know.
Latest COVID-19 news:
Parental strain: The original omicron strain (BA.1)
Prevalence: An estimated 29.7% of new cases this week
What to know: BA.5 was detected in the U.S. at the end of April, experts say, with cases first appearing in the Northeast, then spreading to Southern, Midwestern and Western states. The subvariant quickly become the dominant strain during summer, making up more than 99% of new cases by August. The COVID-19 bivalent boosters were designed to target BA.4, and its twin, BA.4.
Stay up-to-date on COVID news: Sign up for the Coronavirus Watch newsletter
Parental strain: BA.5
Prevalence: 20.1% and 24.1%, respectively
What to know: BQ.1 and BQ.1.1, the newest strains, have gained the attention of top health experts due to its rate of increase since it was first identified in early September.
Dr. Peter Hotez, a pediatrician and dean of the National School of Tropical Medicine at Baylor College of Medicine Houston, called BQ.1.1 the “most likely candidate” to drive a new COVID-19 wave, if that were to happen in the coming months.
Mutation: The strains are descendent of the BA.5 omicron subvariant, but contain a couple of key mutations to the spike protein that health experts speculate may give it an advantage. One such mutation, R346T, has been seen in previous variants and is thought to be associated with immune evasion, said Andrew Pekosz, a virologist and professor at Johns Hopkins Bloomberg School of Public Health.
Parental strain: BA.5
Prevalence: An estimated 5.3% of new cases this week
What to know: “It is also picked up a few mutations we know will evade vaccine induced immunity so we’re keeping an eye on it to see how much of that immunity it will evade,” Pekosz said.
Mutation: BF.7 is another descendent of BA.5 with the R346T mutation.
Moderna: This week, the company shared trial results from over 500 participants ages 19 to 89 that showed:
The Cambridge-based company said its bivalent shot also showed “robust neutralizing activity” against the BQ.1.1 variant, suggesting it may offer some protection against the newest strains edging out BA.5.
It’s “confirming that updated vaccines have the potential to offer protection as the virus continues to evolve rapidly to escape our immunity,” said Moderna’s chief executive officer Stéphane Bancel.
Pfizer-BioNTech: The companies have yet to share data on how its bivalent booster performs against the BQ.1 and BQ.1.1 variants but they released results in early November that showed:
Contributing: Karen Weintraub, USA TODAY. Follow Adrianna Rodriguez on Twitter: @AdriannaUSAT.
Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.
